Background: Blood gas analyzers are o0.ften integrated into point-of-care testing provisions. International standards (ISO 22870 and 15189) with an approach using reproducibility and accuracy data. Results: The coefficients of variation (CVs) were in line with recommendations, except for the repeatability CV for pO 2 . All CVs were below 4%. All comparisons complied with recommendations. Uncertainties of measurement were also validated. Conclusion: Our results met standard requirements and the 12 analyzers were assessed as suitable for point-of-care testing in services of academic medical centers, as exemplified at ClermontFerrand hospital.
Introduction
In France, all biomedical analysis laboratories are governed by the standardization and accreditation regulations set by COFRAC to meet the requirements of the standard EN ISO 15189. However, point-of-care testing (POCT), governed by the standard EN ISO 22870, also requires accreditation by 2020. Although biomedical laboratories have moved forward in the accreditation of analyses carried out in the laboratory, currently very few of them are accredited for POCT. Although Normes Françaises (NF) 22870 is an extension of 15189, and shares many of its requirements, there are some additional requirements specific for POCT. For example, an oversight committee must be created and established prior to installing POCT equipment [1, 2] . The training and accreditation of the
Materials and methods

Analyzers
The GEM PREMIER 4000 analyzers (Werfen, Le Pré-Saint-Gervais, France) are cassette blood gas analysis instruments. Proton concentration [H+] (for Hydrogen potential (pH)), partial pressure of CO 2 (pCO 2 ), sodium (Na + ), potassium (K + ), chloride (Cl -) and ionized calcium (Ca 2+ ) levels are measured by potentiometry; partial pressure of O 2 (pO 2 ) and lactate are measured by amperometry;
hemoglobin (Hb) and oxyhemoglobin (O 2 Hb) by optical absorbance. Twelve analyzers were deployed over 11 sites of the ClermontFerrand university teaching hospital system between February and June 2015. At these 11 deployment sites, each analyzer was assigned a name according to the clinical ward where it was located ( Fig. 1) . At Gabriel Montpied hospital, the instruments were located in the medical intensive care unit (MICU or G2), surgical intensive care unit (SICU or G3), neurological intensive care unit (NICU or G4), cardiovascular surgery intensive care unit (CSICU or G5), cardiovascular surgery operating theater (CVS or G6), medico-technical center (MTC or G7), emergency department (ED or G8), and sport medicine and functional exploration department (SMFED or G9). A backup instrument (BACKUP or G1) was also installed at the SICU. At Estaing hospital, the instruments were installed in the adult intensive care unit (aICU or G10), pediatric intensive care unit (pICU or G11) and maternity ward (MATER or G12). To allow for different specific clinical requirements, not all the analytical values were available on all the analyzers (Fig. 1 ).
Repeatability
Tests to evaluate repeatability were carried out using vials of two distinct levels of controls supplied by Werfen. These were titered aqueous solutions, with physiological analyte concentrations for level 2 and pathological concentrations for level 3, designated respectively GEM System Evaluator 2 (GSE2) and 3 (GSE3). For all the instruments, 30 vials of GEM System Evaluator 2 (Reference no. 00025000102) and 30 vials of GEM System Evaluator 3 (Reference no. 00025000103) were analyzed. The mean of the expected values for our different parameters in solutions GSE2 and GSE3 are presented in Table 1 .
Reproducibility
The reproducibility of the GEM PREMIER 4000 analyzers was assessed independently as soon as the cartridge was loaded (6)(17) (18) . Three internal quality control solutions (A B and D) were programmed for measurements at regular time intervals. For , assays were carried out on solutions A and B. The assays of lactate, hemoglobin (Hb) and oxyhemoglobin (O 2 Hb) were carried out on solutions A and D. The data were then retrieved and processed using the PCSar software supplied by Werfen (V2.0). The means of the expected values for the various parameters in solutions A, B and D are presented in Table 1 .
Accuracy
The GEM PREMIER 4000 analyzers were enrolled in an external quality assessment (EQA) program from ASQUALAB association C. Oris et al.
Practical Laboratory Medicine 10 (2018) [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] (Paris, France). Accuracy is evaluated from EQA result with the percentage bias calculated as (100*(((laboratory result)-(expected result))/(expected result)). For each parameter and at 2 levels (similar to those studied for reproducibility), an average of 3 bias determinations was calculated.
Uncertainty in measurement
Uncertainty in measurement (UM) was evaluated with an approach using both reproducibility and accuracy data. For each parameter and at 2 levels (the same as those studied for reproducibility), results were calculated for concentrations and as a percentage.
(uncertainty from accuracy) ) 
Statistics
The data was analyzed using the VISKALI® software (Viskali ACC, Lyon, France, V5.0). For the accuracy study, we calculated means ( ± SD) of repeatability and reproducibility, together with coefficients of variation (CV) expressed as a percentage. The acceptability criteria chosen were either the desirable specifications of Ricos based on biological variation, in particular for hemoglobin in repeatability and reproducibility tests, and also K + for reproducibility [22] , or the specifications of the French Society of Clinical Biology (SFBC) for all the other repeatability and reproducibility tests as well as accuracy tests [21] . The method comparison was studied by least rectangles regression and calculation of means (+ SD) of differences and ratios. The corresponding graphs were plotted. The comparison of the means was obtained after analysis of the 43 GEM System Evaluator vials on each of the 12 analyzers, and were made with an ANOVA test. Statistical significance of differences was set at p < 0.05.
Results
Repeatability
The Table 2) . Hb was compliant on all the analyzers, but for the desirable specifications of Ricos et al. [22] with CV values below 1.07% (Table 2) . However, for pO 2 , we observed that only three values of CV obtained met SFBC requirements: level 3 for analyzer G2; and levels 2 and 3 for G12 (Table 2) . CV values for repeatability all conformed to the supplier's standards.
Reproducibility
The (Table 4 ). The bias values for Hb were considered as "good" by ASQUALAB. Table 2 Repeatability studies on 12 GEM PREMIER 4000 analyzers (G1-G12) at 2 levels. The results are presented as coefficients of variation (%). Thirty vials of GEM System Evaluator 2 and 30 vials of GEM System Evaluator 3 were analyzed.
[ Result meets desirable specifications of Ricos et al. [22] after conversion of a reproducibility objective into a repeatability objective according to SFBC recommendations [21] (application of the formula CV repeatability = CV reproducibility * 0.75). Table 3 Reproducibility study on the 12 GEM PREMIER 4000 analyzers (G1-G12) on two levels. The results are presented as coefficients of variation in percentage. The reproducibility is evaluated independently as soon as the cartridge is loaded. Three internal quality control solutions were programmed to be measured at regular time intervals. Result meets SFBC specifications [21] . [ Result meets desirable specifications of Ricos et al. [22] . Table 6 Method comparisons between 12 GEM PREMIER 4000 analyzers (G1-G12) and between GEM PREMIER 4000 analyzers and those of the central laboratory (Lab). The comparisons between the GEM PREMIER 4000 analyzers were made on 30 samples. The comparisons between G1 and the central laboratory were made on 50 samples for Na 
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G1 vs. Lab Hb were conformant. The slopes of the allometric plots obtained were close to 1, with intercept close to 0. In addition, the means of differences were close to 0 with relatively low standard deviations. The means of ratios were close to 1, still with low standard deviations ( Table 6 ). For lactate, the data was also conformant for comparisons between GEM PREMIER 4000 analyzers (Table 6 ). For the comparison between GEM PREMIER 4000 G1 and the central laboratory, only the results exploited with a single range of values are presented ( Table 6 ). The analysis of the results over two measurement ranges (0.8-3.8 mmol/L and 3.8-19 mmol/L) revealed a mean of differences close to 0 for the first range and a slight overestimation by Vista relative to G1 for the second range. For Na + and Hb, the data was also conformant for all the comparisons (Table 6 ). We note two slopes greater than 1.1 for comparisons G3 vs. G1 on Na + and G2 vs. G1 on Hb, but these are compensated by the intercepts. We note that on the graphs plotted, nearly all the points lay in the interval [− 2 SD; +2 SD]. In addition, the few exceptions did not change the clinical and biological interpretation of the results. Graphs were presented for comparisons between the central laboratory and G1 ( Supplementary Fig. 1 ), and between 2 GEM PREMIER 4000 analyzers (G1, G3) ( Supplementary Fig. 2 ). The method comparison between the 12 GEM PREMIER 4000 analyzers made on 43 GEM System Evaluator vials (5 level 1, 19 level 2 and 19 level 3), all from the same batch, run on all 12 analyzers showed no statistically significant differences between the analyzers for any of the parameters (Table 7) .
Uncertainty in measurement
Discussion
In the context of deploying 12 point-of-care GEM PREMIER 4000 biological analyzers in the Clermont-Ferrand university teaching hospital, we carried out an on-site method validation (precision and method comparison) to meet the requirements of the standards NF EN ISO 15189 and 22870 [1] [2] [3] [4] [5] [6] . We also evaluated uncertainty in measurement (calculated with an approach using both reproducibility and accuracy data) at 2 levels for each parameter. There is not much data available for some parameters such as pO 2 and O 2 Hb.
The precision study (repeatability, reproducibility) was conducted at two control levels for all our measured parameters, i. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] (CVs) we obtained complied with the SFBC recommendations [22] . As there were no SFBC recommendations for Hb, the CV values were compared and found to be compliant with the recommendations of Ricos et al. [22] . For pO 2 , CV values for reproducibility were compliant with SFBC recommendations [21] . By contrast, the CV values for repeatability were compliant only for 3 levels out of the 24 tested; the other CV values for pO 2 conformed to the supplier's recommendations (4.6%). These supplier's recommendations were based upon guidelines published by the Clinical and Laboratory Standards Institute (Wayne, PA, USA) [23] . All the CV values were below 4%. In addition, in our external quality control surveys (ASQUALAB), no nonconformity was established for this parameter (and the others); since it is highly labile on contact with ambient air it is difficult to perform repeat determinations is. 2 and O 2 Hb. In this study, we propose 24 values of UM (12 values at each of 2 levels calculated with an approach using both reproducibility and accuracy dat a ) for the first time for these 2 parameters. Our values were conformed with the UM calculated by the long-term analytical CV method (using only external quality control material) [25] at 8.4% and 2.9% for pO 2 and O 2 Hb respectively. For method comparisons, because of the large number of analyzers in the Hospital, we opted to make comparisons using a transitive model. In this model, the BACKUP (G1) analyzer was considered as the reference GEM PREMIER 4000 instrument. It was first compared with the automated analyzers at the central laboratory (Vista®, RapidPoint® and XN®), and then with all the other GEM PREMIER 4000 analyzers. All our comparisons between GEM PREMIER 4000 analyzers proved conformant, in both analysis of graphs and processing of numerical data. The recent COFRAC recommendations prescribe simultaneous comparison using an ANOVA test of all the analyzers performing the same analysis in a laboratory. The large number of instruments in our study, the low stability of some parameters, such as pO 2 , and the geographical locations of our analyzers make it difficult to perform such a comparison with blood samples. We decided to compare all the analyzers with 516 quality control vials (43 per analyzer) at three different levels and from the same batch (no statistically significant differences).
The comparison between GEM PREMIER 4000 analyzers and automated central laboratory analyzers was made for the first time. For COFRAC, the analyses can be considered different according to whether they were performed at the central laboratory or at the point of care: neither the matrix (heparinized whole blood for POCT versus heparinized plasma or serum for the central laboratory) nor the analysis method were the same. A comparative study thus remains to be conducted so that hospital laboratory staff can confidently advise clinicians on the simultaneous interpretation of tests done at the central laboratory and at point of care. Overall, the comparisons were conformant. This is particularly important for some parameters such as blood sodium: variations in concentration can occur according to the assay method (direct or indirect potentiometry) [26] . With indirect potentiometry, the results of Na + determinations can vary owing to high blood lipid or protein levels, which modify the plasma water content and underestimate the Na + titer [26] . In addition, as emphasized when vetting users, preanalytical errors can cause discrepancies in results [14] .
In conclusion, in view of the compliance of our data with standard recommendations, this work supports the use of 12 GEM PREMIER 4000 analyzers for POCT in services of academic medical centers, as exemplified by Clermont-Ferrand university teaching hospital.
